|
Market Closed -
Other stock markets
|
After hours 19:05:28 | |||
| 10.46 EUR | -1.78% |
|
10.47 | +0.10% |
| 06-09 | Buy-side pressure on MIB; Unipol and BPER lead gains | AN |
| 06-08 | Clínica Baviera, the copy-paste machine |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.95B | 2.12B | 2.26B | 2.41B | 2.4B | |||||
Total Revenues | 1.95B | 2.12B | 2.26B | 2.41B | 2.4B | |||||
Cost of Goods Sold, Total | 1.46B | 1.59B | 1.71B | 1.83B | 1.83B | |||||
Gross Profit | 487M | 528M | 548M | 581M | 563M | |||||
Selling General & Admin Expenses, Total | 9.81M | 12.39M | 15.94M | 19.66M | 20.05M | |||||
Depreciation & Amortization - (IS) | 143M | 160M | 174M | 193M | 203M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 74.71M | 80.08M | 93.45M | 108M | 106M | |||||
Other Operating Expenses | -5.41M | -9.83M | -9.08M | -6.44M | 2.45M | |||||
Other Operating Expenses, Total | 222M | 242M | 274M | 315M | 332M | |||||
Operating Income | 265M | 286M | 274M | 266M | 232M | |||||
Interest Expense, Total | -27.68M | -30.69M | -44.62M | -57.76M | -59.67M | |||||
Interest And Investment Income | 198K | 598K | 2.08M | 3.88M | 3.95M | |||||
Net Interest Expenses | -27.48M | -30.09M | -42.54M | -53.88M | -55.73M | |||||
Income (Loss) On Equity Invest. | 120K | 309K | 555K | 225K | 228K | |||||
Currency Exchange Gains (Loss) | 1.12M | -2.72M | -3.17M | -2.65M | -3.73M | |||||
Other Non Operating Income (Expenses) | 2.15M | -2.39M | -5.97M | -3.18M | -5.93M | |||||
EBT, Excl. Unusual Items | 241M | 251M | 223M | 207M | 166M | |||||
Restructuring Charges | - | - | - | - | -8.67M | |||||
Merger & Related Restructuring Charges | -11.91M | -5.58M | -2.3M | -3.63M | -1.98M | |||||
Impairment of Goodwill | - | - | - | -1.56M | - | |||||
Gain (Loss) On Sale Of Investments | 1.45M | -45K | 1.66M | -550K | 380K | |||||
Asset Writedown | -4.52M | -333K | -506K | -1.36M | -5.76M | |||||
Other Unusual Items | -2.54M | -949K | -12.43M | -2.96M | -18.67M | |||||
EBT, Incl. Unusual Items | 223M | 244M | 210M | 197M | 132M | |||||
Income Tax Expense | 59.76M | 64.96M | 54.72M | 51.21M | 40.23M | |||||
Earnings From Continuing Operations | 164M | 179M | 155M | 146M | 91.55M | |||||
Earnings Of Discontinued Operations | -5.76M | - | - | - | - | |||||
Net Income to Company | 158M | 179M | 155M | 146M | 91.55M | |||||
Minority Interest | -58K | -255K | 114K | -196K | -217K | |||||
Net Income - (IS) | 158M | 179M | 155M | 145M | 91.33M | |||||
Net Income to Common Incl Extra Items | 158M | 179M | 155M | 145M | 91.33M | |||||
Net Income to Common Excl. Extra Items | 164M | 179M | 155M | 145M | 91.33M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.7 | 0.8 | 0.69 | 0.64 | 0.41 | |||||
Basic EPS - Continuing Operations | 0.73 | 0.8 | 0.69 | 0.64 | 0.41 | |||||
Basic Weighted Average Shares Outstanding | 225M | 224M | 224M | 226M | 223M | |||||
Net EPS - Diluted | 0.69 | 0.79 | 0.69 | 0.64 | 0.4 | |||||
Diluted EPS - Continuing Operations | 0.72 | 0.79 | 0.69 | 0.64 | 0.4 | |||||
Diluted Weighted Average Shares Outstanding | 227M | 227M | 225M | 226M | 226M | |||||
Normalized Basic EPS | 0.67 | 0.7 | 0.62 | 0.57 | 0.47 | |||||
Normalized Diluted EPS | 0.66 | 0.69 | 0.62 | 0.57 | 0.46 | |||||
Dividend Per Share | 0.26 | 0.29 | 0.29 | 0.29 | 0.29 | |||||
Payout Ratio | 31.28 | 32.62 | 42.13 | 45.12 | 71.5 | |||||
American Depositary Receipts Ratio (ADR) | 4 | 4 | 4 | 4 | 4 | |||||
Supplemental Items | ||||||||||
EBITDA | 387M | 417M | 384M | 388M | 359M | |||||
EBITA | 340M | 366M | 330M | 326M | 293M | |||||
EBIT | 265M | 286M | 274M | 266M | 232M | |||||
EBITDAR | 397M | 429M | 400M | 408M | 379M | |||||
Effective Tax Rate - (Ratio) | 26.76 | 26.65 | 26.09 | 26.02 | 30.53 | |||||
Total Current Taxes | 63.44M | 66.9M | 61.63M | 48.03M | 44.69M | |||||
Total Deferred Taxes | -3.68M | -1.95M | -6.9M | 3.18M | -4.46M | |||||
Normalized Net Income | 150M | 156M | 140M | 129M | 104M | |||||
Interest on Long-Term Debt | 10.36M | 11.37M | 14.81M | 19.14M | 20.68M | |||||
Supplemental Operating Expense Items | ||||||||||
Net Rental Expense, Total | 10.8M | 12.39M | 15.94M | 19.66M | 20.05M | |||||
Imputed Operating Lease Interest Expense | 1.5M | 1.95M | 3.75M | 5.56M | 5.36M | |||||
Imputed Operating Lease Depreciation | 9.3M | 10.45M | 12.19M | 14.1M | 14.69M | |||||
Stock-Based Comp., COGS (Total) | 17.11M | 13.07M | 30.28M | 16.13M | 3.61M | |||||
Total Stock-Based Compensation | 17.11M | 13.07M | 30.28M | 16.13M | 3.61M |
- Stock Market
- Stocks
- AMP Stock
- Financials Amplifon S.p.A.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















